Lyrica
Generic Name: pregabalin (pre GAB a lin) Brand Names: LyricaLyricaLyrica
What is Lyrica?
Lyrica (pregabalin) is used to control seizures and to treat fibromyalgia. It is also used to treat pain caused by nerve damage in people with diabetes (diabetic neuropathy) or herpes zoster (post-herpetic neuralgia).
Lyrica is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses in the brain that cause seizures. Lyrica also affects chemicals in the brain that send pain signals across the nervous system.
Lyrica may also be used for other purposes not listed in this medication guide.
Important information about Lyrica
You may have thoughts about suicide while taking Lyrica. Your doctor will need to check you at regular visits. Do not miss any scheduled appointments.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
If you are taking Lyrica to prevent seizures, keep taking the medication even if you feel fine. You may have an increase in seizures if you stop taking Lyrica. Follow your doctor's instructions.
Do not change your dose of Lyrica without your doctor's advice. Tell your doctor if the medication does not seem to work as well in treating your condition.
If you stop taking Lyrica suddenly, your seizures may become worse or you may have withdrawal symptoms. Withdrawal symptoms include headache, sleep problems, nausea, and diarrhea. Do not stop using Lyrica suddenly without first talking to your doctor. You may need to use less and less before you stop the medication completely. Carry an ID card or wear a medical alert bracelet stating that you are taking Lyrica, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are taking a seizure medication.
Please consult with you doctor before starting on any medical treatment.
